INTEGRATED BIOPHARMA INC — Form 8-K
Filed July 2, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
On June 30, 2026, Integrated BioPharma and subsidiary Manhattan Drug Company amended their PNC Bank loan agreement. The existing $4M revolving line of credit was extended from April 15, 2026 to April 14, 2027. A new $250K Convertible Line of Credit Note replaced a matured $500K equipment line; it bears Daily SOFR + 250 bps pre-conversion, converts to term loan after 12 months or when borrower stops drawing. Amendment fee: $4,000 plus $2,500 in counsel costs.
Why this rating
Routine credit facility renewal and replacement. Extends existing borrowing access (material for $3.1M company) but is standard operational refinancing, not transformational. Negative covenants added (sanctions/AML compliance) are regulatory boilerplate.
Extracted items
- 1.01 material agreement
- 1.02 agreement termination
View original filing on SEC.gov ↗
See more from July 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.